Another Blow For Anti-TIGITs As Merck’s Vibostolimab/Keytruda Combo Misses In Phase II NSCLC Trial

But Still Has Potential In Earlier Lines

 
• By Ayisha Sharma
Strings of thread wearing thin, just one string left to connect thread
Investor Sentiment On Anti-TIGITs Is Wearing Thin • Source: Shutterstock

More from Clinical Trials

More from R&D